logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > AIN-457 for chronic non-infectious posterior uveitis – second line

< Back

AIN-457 for chronic non-infectious posterior uveitis – second line

Drugs

Eye Disease

August 2010


AIN-457 is a high-affinity fully human monoclonal antibody which inhibits interleukin- 17A (IL-17A). IL-17A is a pro-inflammatory cytokine secreted exclusively by activated T-cells. AIN-457 is intended for the treatment, or prevention of recurrence of non- infectious posterior segment uveitis in adults (including intermediate uveitis, posterior uveitis and vitritis). It is administered subcutaneously (SC) at 150mg once a week for the first three weeks, then every two weeks; or 300mg for the first three weeks, then monthly.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts